Waldenstrom's macroglobulinemia (WM) is an incurable and rare B-cell lymphoproliferative disorder characterized by BM infiltration of lymphoplasmacytic cells and production of monoclonal immunoglobulin M. Prognostic factors include patient's age, b2-microglobulin level, monoclonal protein level, hemoglobin concentration and platelet count. 1 Therapy is generally reserved for symptomatic patients; however, no demonstration of chemotherapeutic agent or regimen superiority, including autograft, has been reported. 2 We have evaluated the efficacy and feasibility of a therapeutic strategy including high-dose therapy (HDT), anti-CD20 MoAb (rituximab) and autologous PBSC transplant (PBSCT) in upfront patients with WM.
Between April 2001 and October 2003, five male patients with symptomatic WM, who signed informed consent, were enrolled in an open-label trial of HDT (CHOP three courses, rituximab four weekly infusions at 375 mg/m 2 , CY at 4 g/m 2 þ G-CSF) followed by PBSCT, conditioned with melphalan at 200 mg/m 2 . Main pretreatment characteristics were the following: median age 53.5 years (range, 41-66); median b2M 3.86 mg/l (range, 0.6-6.6); median hemoglobin 9.65 g/100 ml (range, 7.3-12.9); median platelets 215 Â 10 Four patients mobilized adequate numbers of stem cells; one patient required a second course of mobilization (CY at 3 g/m 2 þ G-CSF) to collect a sufficient number of PBSCs. All patients underwent autograft with melphalan at 200 mg/m 2 used as preparative regimen at day À2. Median time from diagnosis to PBSCT was 11 months (range 10-13). BM recovery was prompt: reconstitution of neutrophil 4500/ml and platelet 420 000/ml was observed at day 13 (range, 10-33) and day 18 (range, 11-52), respectively. Toxicities were manageable and no treatment-related mortality was observed. In all cases, a partial response 475% was achieved (Table 1) . At a median follow-up of 66 months after PBSCT (range, 56-75), all patients are evaluable, alive without clinical or serological signs of disease progression and maintain a stable partial response.
WM remains an incurable and rare B-cell lymphoproliferative disorder. The Third International Workshop on WM confirmed that treatment must be reserved for symptomatic patients on the basis of individual patient considerations. 4 The aim of treatment is to improve the quality and duration of life with minimal adverse effects in a cost-effective manner. However, the extent to which achievement of CR confers clinical benefit is still debatable. Several factors should be taken into account when choosing the most appropriate primary treatment. These factors include age and possible comorbidities, the presence of cytopenias and thrombocytopenia, the presence of symptoms or signs related to hyperviscosity, the need for rapid disease control owing to severe symptoms, significant splenomegaly or lymphadenopathy, symptomatic peripheral neuropathy and, finally, the possibility of the patient being a candidate for auto-SCT.
Recently, HDT supported by auto-or allo-SCT has been performed in patients with WM. Several patients have received autografts during different phases of their disease and most were heavily pretreated. A variety of preparative regimens have been used, such as high-dose melphalan or CY with or without TBI. This strategy was relatively well tolerated with a low rate of non-relapse mortality and high response rate even in patients who were clearly refractory to several regimens of standard chemotherapy. 5, 6 Furthermore, long-lasting complete responses have been observed in several patients. 7, 8 In a series of 10 patients with advanced WM who received HDT supported by auto-SCT, a 60% probability of surviving without disease progression at 3 years post-HDT was reported. 9 Anti-CD20 MoAb represents one of the major advances in the treatment of B-cell lymphoproliferative disorders; CD20 is expressed on the majority of WM cells, making rituximab a rational treatment for this disease. Results of its efficacy in untreated patients with lymphoplasmacytoid lymphoma, including WM, have been reported by the German Low Grade Lymphoma Study Group, which compared CHOP regimen with or without rituximab. The results showed a significant advantage in favor of immune chemotherapy with response rates of 94 versus 69%, respectively. 10 In this pilot study, we have evaluated the feasibility of stem cell collection after high-dose chemotherapy with CHOP regimen and anti-CD20 MoAb and the efficacy of autograft conditioned by melphalan at 200 mg/m 2 . All patients mobilized an adequate number of peripheral stem cells and obtained a marked response after transplant. It is interesting to note that a patient enrolled in the same study, who refused autograft after rituximab therapy, showed progression of the disease after 12 months of follow-up. Although the number of patients is relatively small, the possible role of autograft in the consolidation and maintenance of response is clearly suggested. Prospective studies are needed to assess whether rituximab should be combined with nucleoside analogs, alkylating agents or both classes of agents. End points of such studies should include not only response rates but also response duration, feasibility of stem cell collection, incidence and severity of infections, and overall survival. Macroglobulinemia has a relatively protracted course, with a median survival ranging from 7 to 10 years in most series. However, in younger patients, alternative therapies, including HDT with PBSCT, should be taken into consideration and could be appropriate early in the course of symptomatic disease.
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